Please login to the form below

Not currently logged in
Email:
Password:

SCCHN

This page shows the latest SCCHN news and features for those working in and with pharma, biotech and healthcare.

Bad news for Innate Pharma as BMS-backed drug stumbles

Bad news for Innate Pharma as BMS-backed drug stumbles

Bad news for Innate Pharma as BMS-backed drug stumbles. Lirilumab combination fails to show additional benefit in SCCHN patients. ... additional benefit compared to Opdivo alone in patients with squamous cell carcinoma of the head and neck (SCCHN).

Latest news

More from news
Approximately 6 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Helen Parfitt joins Research Partnership Helen Parfitt joins Research Partnership

    She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics